Celldex Therapeutics to Present at Upcoming Investor Conferences
Celldex Therapeutics (NASDAQ:CLDX) has announced its management's participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Celldex Therapeutics (NASDAQ:CLDX) has announced its management's participation in two upcoming investor conferences. The company will engage in fireside chats at the following events:
- 2024 Cantor Global Healthcare Conference on Tuesday, September 17th at 8:35 a.m. ET
- TD Cowen's Chronic Urticaria Summit on Friday, September 20th at 10:00 a.m. ET
Live webcasts of these presentations will be accessible on the 'Events & Presentations' page of the 'Investors & Media' section on Celldex's website. Replays will remain available for 90 days after each event, providing investors with extended access to the company's insights and updates.
Details
News Market Reaction – CLDX
The recorded move for CLDX in the trading session of this news was +5.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
2024 Cantor Global Healthcare Conference on Tuesday, September 17th at 8:35 a.m. ET
TD Cowen's Chronic Urticaria Summit on Friday, September 20th at 10:00 a.m. ET
Live webcasts of the presentations will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.